56 Results Inclusion process A flowchart from the inclusion process is displayed in Figure 1. In total, 117 participants are used for analysis of which 20 healthy controls, 49 patients with sarcoidosis are classified as sarcoidosis without SFN and 48 are classified as sarcoidosis with SFN according to the updated Besta criteria.20 Patient characteristics are displayed in Table 1. No significant differences between the three groups could be found, except for sex between patients with sarcoidosis without SFN were more likely to be male than patients with sarcoidosis and probable SFN (OR=3.6, p=0.003). In addition, patients with sarcoidosis, with and without SFN, showed significantly higher BMI than healthy controls. SFN symptoms occurred or were diagnosed at a mean of 6.4±5.3 years after the diagnosis of sarcoidosis. Figure 1 Overview of the inclusion process. Prevalence Prevalence of fatigue in sarcoidosis patients without SFN is 84%, and in patients with sarcoidosis with SFN it is 96% (p=0.049). Particularly, extreme fatigue (FAS>34) is more prevalent in patients with sarcoidosis with SFN compared with patients with sarcoidosis without SFN, resp. 60% and 39% (p=0.03). Mean pain was reported in 33% of patients with sarcoidosis without SFN and up to 85% of patients with sarcoidosis with SFN (p=1.3*10-7). Maximum pain was reported in 45% of patients with sarcoidosis without SFN and up to 92% of patients with sarcoidosis with SFN (p=7.9*10-7). RLS was prevalent in 41% of sarcoidosis patients without SFN and 67% in sarcoidosis patients with SFN (p=0.01). The prevalence of a cognitive impairment was 35% in sarcoidosis patients without SFN and 46% in sarcoidosis patients with SFN (p=0.3), see Figure 2. 3 59 3
RkJQdWJsaXNoZXIy MjY0ODMw